10-QHealthcare

PTC Therapeutics, Inc.

PTCT · Period ending 2026-09-30 · Filed 2026-10-29 · Updated

In short

PTC Therapeutics, Inc. (PTCT) has revenue up 114.5% to $1.7B year on year. Its net margin is 39.4%. Fisclear flags 1 high-severity risk, led by: Total liabilities are 107% of total assets — the balance sheet is heavily leveraged with limited equity cushion. How we calculate this

Valuation

Healthcare
Live · Yahoo Finance

Price

$56.42

P/S (TTM)

4.1x

Price ÷ revenue per share

Beta

0.51

Moderate market correlation

52-Week Range

$56.18$56.42 now$90.87

Decision Context

Altman Z-Score indicates financial distress risk. Review debt levels and cash runway before any position sizing decision.

Based on filing period ending Sept 2026

FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.

PTCT vs

Macro Context

Fed Funds Rate

3.88%

Accommodative

10-Year Treasury

5.13%

2026-10-01

Unemployment

4.2%

Near full employment

CPI Index

336.3

2026-09-01

M2 Money Supply

$23.4T

2026-09-01

The Federal Funds rate stands at 3.88% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 5.13%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 104.0; M2 money supply is $23.4T; CPI index stands at 336.3.

SWOT Analysis — PTCT

Inflationary Boom
Macro lens (Inflationary Boom): Rising costs and tighter margins amplify financial risks in this regime.
✦

Strengths

  • Operating Cash Flow: $711.2M (+760.4% YoY) — Operating cash flow grew 760% — the business generated more cash from day-to-day operations.

  • Net Income: $682.6M (+287.9% YoY) — Profit grew 288% — the company kept more of each dollar earned.

  • EPS (Diluted): $7.78 (+264.5% YoY) — Earnings per share rose 264% — each share earned more.

  • Revenue: $1.7B (+114.5% YoY) — Revenue grew 115% — the company sold more goods or services than the prior year.

  • Total Assets: $2.9B (+70.0% YoY) — Total assets grew 70% — the company's resource base expanded.

◈

Weaknesses

  • R&D spending is 26% of revenue — heavy investment in future growth, but also a drag on current profitability.

◎

Opportunities

No clear opportunities identified at this time.

⚠

Threats

  • Total liabilities are 107% of total assets — the balance sheet is heavily leveraged with limited equity cushion.

Year-over-Year Changes

Operating Cash Flow

$711.2M

was -$107.7M

+760.4%

Operating cash flow grew 760% — the business generated more cash from day-to-day operations.

Net Income

$682.6M

was -$363.3M

+287.9%

Profit grew 288% — the company kept more of each dollar earned.

EPS (Diluted)

$7.78

was $-4.73

+264.5%

Earnings per share rose 264% — each share earned more.

Revenue

$1.7B

was $806.8M

+114.5%

Revenue grew 115% — the company sold more goods or services than the prior year.

Total Assets

$2.9B

was $1.7B

+70.0%

Total assets grew 70% — the company's resource base expanded.

Risk Flags

1 high · 0 medium · 1 low
  • ⚠ High

    Total liabilities are 107% of total assets — the balance sheet is heavily leveraged with limited equity cushion.

  • ○ Low

    R&D spending is 26% of revenue — heavy investment in future growth, but also a drag on current profitability.

Technical Signals

Daily closes · 1-year data

PTC Therapeutics, Inc.: common questions

Is PTC Therapeutics, Inc. profitable?

Yes. PTC Therapeutics, Inc. made a net profit of $683M in its latest fiscal year (fiscal 2025), a net margin of 39.4%.

Is PTC Therapeutics, Inc.'s revenue growing?

Yes. Revenue grew 114.5% year on year, to $1.7B.

Does PTC Therapeutics, Inc. pay a dividend?

No dividend is currently expected from PTC Therapeutics, Inc., according to the latest market data.

What are the main risks for PTC Therapeutics, Inc.?

Fisclear's checks flag 1 medium- or high-severity risk. The most serious: Total liabilities are 107% of total assets — the balance sheet is heavily leveraged with limited equity cushion.

Answers are generated from the figures in this report (updated 5 Nov 2026). Information, not investment advice.

Latest News

via Finnhub

Filing History — PTCT

Get the weekly digest

5 company reports + macro context every week, free. No spam.

  • Unlimited goal simulations
  • 5 free company report summaries per day
  • Weekly financial insights newsletter

External Links

Trade PTCT

Links open broker research pages. Not an endorsement or recommendation.

Research PTC Therapeutics, Inc.

Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.